Telix is developing a pipeline of Molecularly-targeted radiation (MTR) products to image and treat cancer.
What is MTR?
In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumours and delivers a radioactive payload in a highly selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic or both.
Advantage of MTR therapeutics
Most targeted therapies only kill a subset of cancer cells in the tumour microenvironment. MTR therapies are designed to destroy the tumour target plus adjacent tumour and supportive cells – this is called the “bystander effect.”
The result is a highly potent and selecting cancer-killing effect, as well as recruitment of the body’s immune system to augment the treatment process.
- Effective and well-tolerated
- Far more localised than traditional external-beam radiation oncology, superior treatment of metastatic disease
- Delivers both imaging and therapy
- Offer precise, modern imaging to map a patient’s cancer with a high degree of accuracy to inform treatment decisions
- Can be used in combination with other therapeutic strategies, such as immuno-oncology drugs (e.g. checkpoint inhibitors)
- Charles Sturt University series on theranostics for patients, families and carers.
- Theranostics for prostate cancer – Professor Richard Baum
- Review article by Professor Richard Baum and Harshard Kulkarni on molecular imaging and personalised radionuclide therapies
- Paper by Professor Rodney Hicks and colleagues on somatostatin receptor imaging with 68Gallium DOTATATE and PET/CT
With the exception of Illuccix® (TLX591-CDx) in Australia, none of Telix’s products have received a marketing authorisation in any jurisdiction. Any use of Telix products is on an investigational basis or for use in approved clinical trials.